Buenos Aires - Delayed Quote ARS

Pfizer Inc. (PFE.BA)

6,965.50 +231.00 (+3.43%)
At close: April 19 at 4:59 PM GMT-3
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
58,496,000.00
58,496,000.00
100,330,000.00
81,288,000.00
41,651,000.00
Cost of Revenue
24,954,000.00
24,954,000.00
34,344,000.00
30,821,000.00
8,484,000.00
Gross Profit
33,542,000.00
33,542,000.00
65,986,000.00
50,467,000.00
33,167,000.00
Operating Expense
30,183,000.00
30,183,000.00
28,714,000.00
26,763,000.00
24,338,000.00
Operating Income
3,359,000.00
3,359,000.00
37,272,000.00
23,704,000.00
8,829,000.00
Net Non Operating Interest Income Expense
-585,000.00
-585,000.00
-987,000.00
-1,255,000.00
-1,376,000.00
Other Income Expense
-1,716,000.00
-1,716,000.00
-1,556,000.00
1,763,000.00
-415,000.00
Pretax Income
1,058,000.00
1,058,000.00
34,729,000.00
24,311,000.00
7,036,000.00
Tax Provision
-1,115,000.00
-1,115,000.00
3,328,000.00
1,852,000.00
370,000.00
Net Income Common Stockholders
2,119,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Diluted NI Available to Com Stockholders
2,119,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Basic EPS
0.76
0.76
11.18
7.84
3.46
Diluted EPS
0.74
0.74
10.94
7.70
3.42
Basic Average Shares
2,821,500.00
2,821,500.00
2,804,000.00
2,800,500.00
2,777,500.00
Diluted Average Shares
2,821,500.00
2,821,500.00
2,866,500.00
2,854,000.00
2,816,000.00
Total Expenses
55,137,000.00
55,137,000.00
63,058,000.00
57,584,000.00
32,822,000.00
Net Income from Continuing & Discontinued Operation
2,119,000.00
2,119,000.00
31,372,000.00
21,979,000.00
9,159,000.00
Normalized Income
5,997,890.00
5,997,890.00
35,039,856.00
24,999,276.00
8,205,548.32
Interest Income
1,624,000.00
1,624,000.00
251,000.00
36,000.00
73,000.00
Interest Expense
2,209,000.00
2,209,000.00
1,238,000.00
1,291,000.00
1,449,000.00
Net Interest Income
-585,000.00
-585,000.00
-987,000.00
-1,255,000.00
-1,376,000.00
EBIT
3,267,000.00
3,267,000.00
35,967,000.00
25,602,000.00
8,485,000.00
EBITDA
8,000,000.00
9,557,000.00
41,031,000.00
30,793,000.00
13,262,000.00
Reconciled Cost of Revenue
24,954,000.00
23,397,000.00
32,889,000.00
29,330,000.00
7,055,000.00
Reconciled Depreciation
4,733,000.00
6,290,000.00
5,064,000.00
5,191,000.00
4,777,000.00
Net Income from Continuing Operation Net Minority Interest
2,134,000.00
2,134,000.00
31,366,000.00
22,413,000.00
6,630,000.00
Total Unusual Items Excluding Goodwill
-4,891,000.00
-4,891,000.00
-4,064,000.00
-2,799,000.00
-1,663,000.00
Total Unusual Items
-4,891,000.00
-4,891,000.00
-4,064,000.00
-2,799,000.00
-1,663,000.00
Normalized EBITDA
12,891,000.00
14,448,000.00
45,095,000.00
33,592,000.00
14,925,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-1,027,110.00
-1,027,110.00
-390,144.00
-212,724.00
-87,451.68
12/31/2020 - 1/7/2008
Yahoo Finance Plus Essential access required. Unlock Access